Merck's MK-7243 Significantly Reduced Allergy Symptoms in Adults and Children in Pivotal Phase III Study

Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501